Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

PSTI 2.45 -0.01 (-0.41%)
price chart
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4%
Pluristem Therapeutics, Inc. (PSTI - Snapshot Report) was a big mover last session, as the company saw its shares rise over 7% on the day.
Will Pluristem Therapeutics (PSTI) Crush Estimates at Its Next Earnings Report?
After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company's earnings prospects.
Related articles »  
Pluristem Therapeutics Inc. (PSTI): The Bull Case For Pluristem Therapeutics
One of the problems that the technology faced was that the cell culture process created degradation in the quality of their therapeutic ability.
Related articles »  
Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel ...
This is the second regulatory approval for the company's 3D cell manufacturing process, having received approval in Germany last January.
Related articles »  
Pluristem Therapeutics Sets New 12-Month Low at $2.42 (PSTI)
Pluristem Therapeutics Inc (NASDAQ:PSTI) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.
Related articles »  
Pluristem Therapeutics Inc. (PSTI): Mesoblast Is No Match For Pluristem's IP ...
Last week, Pluristem Therapeutics Inc. (NASDAQ:PSTI) won a method of use patent in Australia for its PLX cells in ischemia, where obstruction of blood vessels to an organ causes tissue death.
Related articles »  
Pluristem Therapeutics Inc. (PSTI) news: Pluristem's Preeclampsia Effort ...
The power of the placenta rings truer than ever in an upcoming therapeutic indication planned by Pluristem Therapeutics, Inc. (NASDAQ:PSTI) using PLX cell therapy for treating pregnant women with preeclampsia, a leading cause of maternal and infant ...
Related articles »  
Pluristem Therapeutics Inc.: Pluristem Granted Patent in Singapore for its 3D ...
HAIFA, ISRAEL, December 1, 2014 --Pluristem Therapeutics Inc . (NasdaqCM: PSTI; TASE: PSTI), a leading developer of placenta-based cell therapy products, announced today it has been granted a patent in Singapore titled "Methods for Cell Expansion ...
Related articles »  
Pluristem Therapeutics Inc. (PSTI): Pluristem's Positive Data Could Open ...
In a few short weeks, Pluristem Therapeutics (NASDAQ:PSTI) will announce landmark data using its PLX cell therapy on gluteal muscle injury that results from hip replacement surgery.
Pluristem Therapeutics Inc. (PSTI): Celgene's And Osiris' IP Positions ...
Intellectual property is an invaluable asset for a biotechnology company, where a large percentage of operating costs go to research and development in hopes of creating the next big drug.
Related articles »